Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Negotiating Price Negotiation: Why the Democrats Will Struggle to Pressure Part D Prices

This article was originally published in RPM Report

Executive Summary

The new Congress wants to make federal price negotiation under Medicare a reality. But it won't be easy. Big Pharma should expect plenty of interference from the Democrats in Part D, but it is hard to see a meaningful impact on prices in the near term.

You may also be interested in...



So That's What "Non-Interference" Means: CMS Defines Loaded Term in Proposed Part D Rule

The 700-page Part D proposed rule does much more than change the "protected" class list. Among many other provisions, it spells out how CMS interprets the infamous "non-interference" clause.

Part D Rebates: Defeat In Finance Committee May Set Key Precedent

Democratic Sen. Bill Nelson of Florida may have made a tactical error in bringing up an amendment to mandate drug rebates under Medicare Part D during the Senate Finance Committee’s markup of health reform legislation.

Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't

The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS080000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel